VolitionRx announces availability of new press release

VolitionRX Ltd

VolitionRX Ltd

VNRX

0.00
  • VolitionRx released a July 7, 2026 announcement citing a new study on Nu.Q Cancer’s prognostic value in newly diagnosed lung cancer patients.
  • The paper, “Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence”, is under peer review.
  • Volition flagged completed clinical certification at Hospices Civils de Lyon, a step toward a France reimbursement submission under the RIHN framework.
  • Management referenced a direct sales model targeting about EUR 50 per test in France, with reimbursement seen as a key commercialization milestone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607070817PR_NEWS_USPR_____LN99263) on July 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.